The study, published in Cell Death Discovery, focuses on lens epithelial cells, the thin layer of cells that covers the front of the lens and maintains its transparency throughout life. When these cells die or become inflamed, the structural integrity and clarity of the lens suffer. The researchers suspected that a form of inflammatory cell death called pyroptosis might be a key driver of the damage, and they traced the process back to one of the immune system’s most sensitive alarm systems: the detection of stray DNA inside the cell.

Under normal conditions, DNA belongs in the nucleus and in mitochondria, the cell’s energy-producing compartments. When fragments of genetic material appear in the cytoplasm — the fluid surrounding these compartments — it usually signals danger, either from an invading pathogen or from internal injury. A protein called cyclic GMP-AMP synthase, or cGAS, acts as the cytoplasmic DNA sensor. Upon binding stray DNA, cGAS produces a small messenger molecule that activates a protein on the endoplasmic reticulum known as STING, which in turn switches on inflammatory signaling pathways. This cGAS-STING system is a cornerstone of innate immunity, but when it fires inappropriately it can turn a cell’s own tissues into targets.

The first evidence came from human tissue. Examining anterior lens capsules removed from patients with diabetic cataract, the team found that the lens epithelial cells showed significantly elevated levels of cGAS, STING, NLRP3, caspase-1, and gasdermin D — a lineup of proteins that together define the inflammatory pathway the researchers wanted to interrogate. NLRP3 is the sensor component of a multiprotein assembly called the NLRP3 inflammasome, which assembles in response to cellular stress. Once assembled, the inflammasome activates caspase-1, an enzyme that both processes inflammatory signaling molecules and cleaves gasdermin D, the executioner protein of pyroptosis.

Pyroptosis is a particularly destructive form of programmed cell death. Unlike the quiet, tidy dismantling of apoptosis, pyroptosis ends with gasdermin D punching large pores in the cell membrane. The cell swells, bursts, and spills its contents — including mature forms of the inflammatory messengers interleukin-1β and interleukin-18 — into the surrounding tissue. This release amplifies inflammation, recruiting and activating neighboring cells and potentially damaging the extracellular matrix that keeps the lens transparent. Lactate dehydrogenase, an enzyme normally confined inside healthy cells, leaks out through these pores and serves as a convenient laboratory marker of membrane rupture.

To test whether high glucose could trigger this entire cascade in lens cells, the researchers exposed human lens epithelial cells to elevated sugar concentrations in culture. The exposure produced exactly the sequence they predicted: DNA accumulated in the cytoplasm, including fragments released from damaged mitochondria; cGAS-STING signaling switched on; the NLRP3 inflammasome and its adaptor protein ASC accumulated; caspase-1 and gasdermin D were cleaved into their active forms; lactate dehydrogenase leaked into the culture medium; and the cells secreted elevated amounts of interleukin-1β and interleukin-18. In short, high glucose transformed the lens epithelium’s own protective cells into casualties of an innate immune response gone awry.

The causal question remained: was the inflammasome actually responsible for the cell death, or merely a bystander? The team answered it with small interfering RNAs, synthetic molecules that silence specific genes. When they knocked down NLRP3 in lens epithelial cells under high-glucose conditions, the pyroptotic response collapsed. Levels of ASC, cleaved caspase-1, and cleaved gasdermin D fell, lactate dehydrogenase release dropped, and secretion of interleukin-1β and interleukin-18 diminished. Silencing cGAS or STING produced a similar protective effect and, critically, suppressed activation of the NLRP3-caspase-1-gasdermin D axis. That placement — upstream of the inflammasome — suggests that the DNA-sensing pathway acts as an initiator that feeds into and drives inflammasome activation in the diabetic lens.

Cell culture experiments, however convincing, cannot capture the complexity of a living eye. The researchers therefore turned to a diabetic rat model, in which elevated blood sugar produces lens clouding resembling the human condition. Delivering small interfering RNAs targeting cGAS, STING, or NLRP3 to the animals significantly reduced lens opacity and improved the histopathological appearance of the lens epithelium and cortex under the microscope. The improvement across all three molecular targets strengthens the argument that the pathway operates as an integrated axis in vivo, rather than as isolated biochemical events, and demonstrates for the first time in a living system that interrupting this signaling at multiple points can preserve lens clarity.

The findings carry real therapeutic weight. Current drug development efforts against inflammatory diseases increasingly target cGAS-STING and NLRP3, and inhibitors of both pathways are in various stages of preclinical and clinical evaluation for conditions ranging from gout to neurodegeneration. The new work suggests that such compounds — or gene-silencing approaches like the siRNAs used here — could one day complement glucose control as a strategy to slow or prevent diabetic cataract. Because the pathway was validated at three separate nodes in animal models, it offers several potential points of pharmacological intervention, each of which might be exploited depending on safety and delivery considerations.

Important caveats remain before the laboratory results can inform clinical practice. The animal work used rats, whose lenses differ in some respects from human lenses, and the duration of intervention was limited relative to the years over which diabetic cataract develops in patients. Delivering RNA therapeutics or small-molecule inhibitors to the lens in a safe, sustained way is an unsolved engineering problem, and innate immune pathways such as cGAS-STING perform essential protective functions elsewhere in the body, so systemic suppression carries risks that local, eye-targeted approaches would need to avoid. Nevertheless, by identifying cytosolic DNA accumulation as the trigger and tracing a complete signaling route from cGAS through STING and the NLRP3 inflammasome to gasdermin D–mediated rupture of lens epithelial cells, the study reframes diabetic cataract not simply as a passive consequence of sugar-induced protein damage, but as an active, targetable inflammatory disease — a conceptual shift that could reshape how researchers search for the first true drug treatment for this blinding complication.

Subject of Research: The role of cGAS-STING signaling and NLRP3 inflammasome-mediated pyroptosis in high glucose-induced diabetic cataract

Article Title: Inhibition of cGAS-STING signaling and NLRP3 inflammasome-mediated pyroptosis reduces lens opacity and inflammation in high glucose-induced cataract

Article References: Yu, Y., Chen, H., Hu, L., Gao, S., Xiao, Y., Wu, X., Yu, M., Lin, H., & Liu, Z. (2026). Inhibition of cGAS-STING signaling and NLRP3 inflammasome-mediated pyroptosis reduces lens opacity and inflammation in high glucose-induced cataract. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03382-7

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03382-7

Keywords: diabetic cataract, cGAS-STING, NLRP3 inflammasome, pyroptosis, lens epithelial cells, gasdermin D, caspase-1, mitochondrial DNA, interleukin-1β, siRNA, inflammation, lens opacity

The research, led by Yan Qian and colleagues, focuses on the NLRP3 inflammasome, a multiprotein complex inside immune cells that functions as one of the body’s most potent alarm systems. When the inflammasome detects cellular danger, it triggers the release of interleukin-1 family cytokines, signaling molecules that recruit and energize other immune cells to fight invading pathogens. The complex also activates gasdermin D, a protein that punches pores in the cell membrane and drives an inflammatory form of cell death called pyroptosis. This dual output is powerful but double-edged: too little inflammasome activity leaves an infection unchecked, while too much can flood tissue with inflammatory damage and kill off the very immune cells needed to sustain the response.

What the researchers discovered is that exercise does not simply amplify or suppress this system. Instead, it pushes the NLRP3 inflammasome into what they describe as a hyperactivation-like state during infection. In this state, the inflammasome continuously secretes inflammatory cytokines over an extended period, providing a sustained immune signal, while paradoxically reducing the amount of pyroptotic cell death among immune cells. The result is an immune response that is both louder and longer-lasting, yet less self-destructive, giving the host a decisive advantage in clearing pathogens.

To understand how exercise produces this unusual configuration, the team traced the biochemical pathway step by step. They found that physical exercise enhances the binding between CNDP2, an enzyme known for its role in peptide metabolism, and gasdermin D, the pore-forming executor of pyroptosis. This interaction promotes the production of γ-Glu-Cys, a small metabolite that sits one biochemical step upstream of glutathione, the cell’s master antioxidant. In other words, the exercise-induced enzyme-substrate partnership channels cellular chemistry toward the accumulation of a specific protective molecule precisely where and when the inflammasome is firing.

The next link in the chain involves mitochondria, the energy-producing organelles that are also frequent casualties of inflammasome activation. During canonical inflammasome activation, gasdermin D attacks the mitochondrial inner membrane, and a protein called cyclophilin D, or CypD, opens a pore in that membrane known as the mitochondrial permeability transition pore. When these events coincide, mitochondrial DNA leaks into the cytoplasm, and this escaped DNA acts as a second signal that can drive the inflammasome into destructive overdrive, accelerating pyroptosis and undermining the immune response from within.

The study shows that γ-Glu-Cys intervenes at exactly this vulnerable point. The metabolite binds directly to CypD and blocks its association with gasdermin D. With that interaction disrupted, the mitochondrial inner membrane is spared further damage during inflammasome activation. Mitochondrial DNA leakage is therefore limited rather than catastrophic. This restraint is what allows the NLRP3 inflammasome to enter its hyperactivation-like state: the complex keeps producing cytokines, but the runaway feedback loop of mitochondrial damage and cell death is kept in check. The immune cell survives longer and keeps signaling, which the authors identify as the crucial advantage exercise confers during infection.

The experimental logic supporting this model involved connecting each node of the pathway to infection outcomes. When the CNDP2–gasdermin D interaction was strengthened, as it is by exercise, γ-Glu-Cys accumulated, mitochondrial integrity was preserved, cytokine secretion persisted, and immune cells resisted pyroptosis, all of which translated into improved host defense. The findings thus map a complete causal route from a physiological intervention to a molecular metabolite to a subcellular interaction to a systems-level immune phenotype.

Beyond its mechanistic elegance, the work carries practical implications. Because the pathway links exercise intensity to the magnitude of the inflammasome’s hyperactivated state, the authors suggest that their findings could provide standards for guiding exercise intensity in ways that deliberately improve anti-infection capability. Rather than treating exercise as a diffuse lifestyle factor, clinicians might one day calibrate training prescriptions to optimize this metabolite-driven immune tuning, particularly for vulnerable populations such as the elderly or the immunocompromised, though the researchers note that translating these standards into practice remains future work.

The study also reframes a long-standing puzzle in immunology: why moderate exercise protects against infection while exhaustive exercise sometimes appears to increase susceptibility. If the benefit depends on a finely balanced metabolite pathway that preserves mitochondria while sustaining cytokine output, then excessive exercise could plausibly push the same machinery past its protective range, a hypothesis the authors’ framework makes testable. The identification of γ-Glu-Cys as the pivot molecule likewise opens the door to pharmacological questions, since a metabolite with a defined protein target invites exploration of whether its effects could be mimicked therapeutically.

For now, the study stands as one of the most complete molecular narratives yet assembled for exercise-induced immune enhancement, connecting physical exertion, a peptide-metabolizing enzyme, a gasdermin, a mitochondrial pore protein, and a master immune sensor into a single coherent pathway. It demonstrates that the immune benefits of exercise are not vague correlations but the product of specific, manipulable biochemistry, and it hands researchers a concrete set of molecular targets for the next generation of studies on how movement fortifies the body against infection.

Subject of Research: Molecular mechanism by which exercise enhances anti-infection immunity through CNDP2 metabolite-mediated inflammasome regulation

Article Title: Exercise promotes host anti-infection activity through CNDP2 metabolite-mediated inflammasome hyperactivation

Article References: Qian, Y., Cheng, X., Liu, Q., Wang, C., Kong, C., Li, M., Geng, X., Ai, L., Zhao, M., Wang, S., Jiang, D., & Xia, P. (2026). Exercise promotes host anti-infection activity through CNDP2 metabolite-mediated inflammasome hyperactivation. PLOS Pathogens, 22(10), e1014554. https://doi.org/10.1371/journal.ppat.1014554

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014554

Keywords: exercise, immunity, NLRP3 inflammasome, CNDP2, gasdermin D, gamma-Glu-Cys, mitochondria, pyroptosis, CypD, infection, cytokines, PLOS Pathogens

Pyroptosis is not an ordinary death. It is a programmed, highly inflammatory form of cell suicide that serves as an alarm system for the immune system. It is triggered when pathogen-associated or danger-associated molecular patterns are detected in the cytosol, the fluid interior of the cell. Upon sensing these threats, caspase-1 in humans and mice, along with caspase-4, caspase-5 in humans and caspase-11 in mice, cleaves a protein called gasdermin D, or GSDMD. This cleavage releases the N-terminal fragment of GSDMD, which migrates to the cell membrane and oligomerizes into pores. These pores disrupt the osmotic balance of the cell, allowing water to rush in, causing the cell to swell, burst and spill its inflammatory contents, including the potent cytokine interleukin-1β, into the surrounding tissue.

While this fiery demise is useful for containing infection, overactive pyroptosis is a driver of disease. Excessive pyroptotic cell death has been implicated in atherosclerosis, arthritis, Alzheimer’s disease, HIV and various types of cancer. This has made the inflammatory caspases attractive drug targets, and caspase inhibitors have captured the attention of scientists and clinicians alike. Yet developing safe and clinically effective caspase inhibitors has proven remarkably difficult. The central problem is selectivity. Caspases are a family of proteases with overlapping substrate preferences, which makes it difficult to inhibit one member without affecting others. Many existing inhibitors block caspases involved in both pyroptosis and apoptosis, the quiet, non-inflammatory form of cell death that is essential for development and immunity. Worse, inhibiting caspase-8 can sensitize cells to necroptosis, another damaging form of cell death, potentially trading one pathology for another.

To escape this trap, Groborz and colleagues took a rational, chemistry-driven approach. They exploited the known substrate preferences of individual caspases to synthesize a library of roughly one hundred tetrapeptides, each attached to an acyloxymethyl ketone, or AOMK, group. These reactive chemical groups allow the tetrapeptides to bind covalently and irreversibly to the active sites of their target caspases, ensuring durable inhibition. From this library, several candidates emerged that suppressed cell death driven by caspase-1, caspase-4 and caspase-11 while leaving staurosporine-induced apoptosis untouched. One of the most potent, named KGR-3, stood out as a strong inhibitor of caspase-1 and caspase-4.

The detailed characterization of KGR-3 revealed just how precisely it worked. The compound blocked pyroptosis by preventing the cleavage of GSDMD, thereby stopping pore formation at its source. It also attenuated the release of interleukin-1β and lactate dehydrogenase, a standard marker of membrane rupture, in response to activation of the NLRP3 and NLRP1 inflammasomes, the multiprotein complexes that activate caspase-1. Crucially, KGR-3 did not interfere with hallmarks of apoptosis such as caspase-1-induced blebbing or caspase-3 cleavage, nor did it affect necrosis triggered by listeriolysin O, a bacterial toxin. Cells treated with KGR-3 not only avoided death; their swelling and lysis were suppressed and they continued to grow and divide. The inhibitor appeared to grant cells a genuine reprieve rather than merely delaying the inevitable.

Yet a puzzling observation threatened to undermine the whole story. KGR-3 and its chemical siblings showed limited permeability in healthy cells, meaning they should not have been able to reach the intracellular caspases they so effectively inhibited. This paradox led the authors to a bold hypothesis: pyroptosis itself facilitates inhibitor uptake. Like a Trojan horse being wheeled through the gates of a besieged city, the caspase inhibitors were exploiting the very pores formed during pyroptosis to slip inside and reach the caspases driving the process. To test this idea, the researchers used propidium iodide and YOYO-1, two small fluorescent molecules that normally cannot cross intact membranes. Both entered cells in a GSDMD-dependent manner, providing strong evidence that gasdermin pores admit small molecules from the outside.

The story became even more sophisticated when the researchers examined what happened to the membrane damage inflicted along the way. In KGR-3-treated cells, GSDMD-induced membrane injury was repaired by the endosomal sorting complexes required for transport, known as the ESCRT machinery. This repair system is a conserved cellular mechanism that seals small membrane wounds. When the researchers expressed dominant-negative versions of the ESCRT proteins VPS4A and CHMP3, KGR-3 lost its protective effect, and pyroptosis proceeded. This finding challenges the simple binary view of pyroptosis as an irreversible commitment to death. Instead, it suggests a pharmacologically accessible window between the initiation of pyroptosis and final lysis, a period during which GSDMD pores disrupt the membrane enough to admit the drug, but not so extensively that repair by ESCRT becomes impossible. Recent research has independently highlighted the reversibility of GSDMD pore formation and shown that ESCRT can limit pyroptosis and cytokine secretion after inflammasome activation, lending further support to this model.

There is also an elegant pharmacological lesson hidden in the poor permeability of these compounds. In traditional drug development, limited cell permeability is considered a weakness. Here, it becomes a feature. Because the inhibitors can only enter cells whose membranes have already been breached by gasdermin pores, they are restricted to unhealthy cells, those actively undergoing pyroptosis, and are excluded from healthy neighbors. This built-in targeting mechanism could limit the off-target effects that have plagued broader caspase inhibitors, offering a new design principle: drugs need not always be membrane permeable if the disease state itself creates the doorway. The study thus overturns the conventional assumption that any drug aimed at an intracellular target must be able to cross an intact plasma membrane.

Translating the concept into animals required further chemical refinement. KGR-3 itself showed limited efficacy in vivo, but another tetrapeptide from the library, KGR-53, proved more promising. It was selected for animal testing because of its potent inhibition of caspase-11, a key mediator of endotoxic shock induced by lipopolysaccharide in mice. Because negatively charged compounds are transported inefficiently through GSDMD pores, the team designed a derivative called KGR-53P that lacks a negative charge. This optimized compound inhibited GSDMD cleavage and blocked the caspase-1- and caspase-11-dependent secretion of interleukin-1β and interleukin-18, while leaving both intrinsic and extrinsic apoptosis intact. In a mouse model of endotoxic shock, a condition driven by runaway caspase-11 activity, this selectivity could prove decisive.

The work is not without caveats, as Henry and O’Neill note in their highlight. First, the entry of KGR-3 through GSDMD pores has not been directly visualized. Although the GSDMD-dependent uptake of propidium iodide and YOYO-1 strongly implies that the pores serve as entry routes for small molecules, attempts to image KGR-3 itself failed because fluorescent tagging compromised the compound’s potency, permeability or toxicity. Second, KGR-53 showed evidence of liver toxicity in vivo, and it remains unclear whether this toxicity stems from the AOMK chemistry, an off-target effect or an entirely different mechanism. These open questions will shape the next phase of research. Even so, the conceptual advance is considerable. If the window between pyroptosis initiation and lysis can be reliably exploited, a new class of anti-inflammatory drugs could emerge that intervene only where inflammation is already burning, leaving healthy tissue untouched. The gates that pyroptosis opens may, in the end, become the route by which medicine tames it.

Subject of Research: Selective inflammatory caspase inhibitors that enter cells through gasdermin D pores to inhibit pyroptosis

Article Title: A Trojan horse story: does pyroptosis open the gates to its own inhibition?

Article References: Henry, Ó. C., & O’Neill, L. A. J. (2026). A Trojan horse story: does pyroptosis open the gates to its own inhibition?. Cell Research. https://doi.org/10.1038/s41422-026-01302-z

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01302-z

Keywords: pyroptosis, gasdermin D, inflammatory caspases, caspase-1, caspase-11, GSDMD, ESCRT, inflammasome, cell death, innate immunity, drug design, inflammation

NLRP3, short for NOD-like receptor pyrin domain 3, is a pattern-recognition protein that assembles into a multi-protein machine known as an inflammasome. When the sensor detects danger signals, ranging from cholesterol crystals to products of cellular damage, it triggers the enzyme caspase-1, which in turn processes the inflammatory messengers interleukin-1 beta and interleukin-18. Caspase-1 also cleaves Gasdermin D, producing an N-terminal fragment that punches pores in the cell membrane and initiates a fiery form of cell death called pyroptosis. Inflammasome hyperactivation is already infamous in human medicine: inherited gain-of-function mutations in NLRP3 cause cryopyrin-associated periodic syndromes, devastating autoinflammatory diseases. What has been missing is direct in vivo evidence showing what happens when this same sensor is chronically overactive specifically within the smooth muscle cells of the artery wall.

To answer that question, the team, led by Yun-Ting Wang, Xiang Li, and Yang Zhang, engineered a mouse carrying an Nlrp3 gain-of-function mutation, the L351P variant, exclusively in vascular smooth muscle cells by combining the knock-in allele with a Myh11-driven Cre recombinase. This model, dubbed Nlrp3-SMKI, allowed the investigators to isolate the contribution of smooth muscle-intrinsic inflammasome signaling from the contributions of immune cells and endothelium. The researchers then subjected these animals and control mice to partial ligation of the carotid artery under hypercholesterolemic conditions, a well-established surgical model that produces disturbed blood flow, endothelial dysfunction, and rapid development of neointimal lesions that mimic human restenosis and early atherosclerosis.

The results were striking even before any surgical injury was applied. In unligated arteries of the mutant mice, the team already detected elevated caspase-1 activation-associated signaling, indicating that the hyperactive inflammasome was quietly simmering within the vessel wall under baseline conditions. When the carotid artery was partially ligated, this inflammatory activity surged further, revealing that the gain-of-function mutation primed the smooth muscle cells to mount an exaggerated response to vascular stress. In other words, the mutation did not merely add inflammation after injury; it fundamentally lowered the threshold at which the arterial wall responded to danger.

Downstream of caspase-1, the pathological cascade unfolded across multiple fronts. The ligated arteries of the mutant mice showed heightened vascular inflammation, marked by increased expression of VCAM1, an adhesion molecule that recruits inflammatory cells, and by greater accumulation of macrophage-associated signals within the vessel wall. The researchers also documented enhanced Gasdermin D and Gasdermin D N-terminal-associated signaling, the molecular signature of pyroptotic cell injury, together with increased numbers of TUNEL-positive cells indicating cell death. These findings weave smooth muscle cells into the inflammatory fabric of the lesion in a way that earlier cell-culture studies had suggested but could not prove in a living organism.

The functional consequence was a dramatically worsened structural outcome. Neointimal lesion growth was significantly exacerbated in the mutant animals, as measured by increased intimal area and an elevated intima-to-media ratio, the standard metrics of pathological vessel thickening. Because the only genetic difference between the experimental and control groups was the hyperactive Nlrp3 allele confined to smooth muscle cells, the study provides compelling causal evidence that smooth muscle-intrinsic inflammasome signaling is not a passive bystander in intimal hyperplasia but an active driver of lesion expansion.

Perhaps the most clinically provocative finding concerned lipid metabolism. The injured arteries of the mutant mice accumulated more lipid and displayed foam cell-like remodeling, including within regions containing alpha-smooth muscle actin-positive cells. Foam cells, the cholesterol-engorged cells that define atherosclerotic plaques, have traditionally been associated with macrophages, but a growing body of literature shows that vascular smooth muscle cells can undergo phenotypic switching and adopt foam cell characteristics, becoming a major and underappreciated cellular component of plaques. The new data indicate that NLRP3 hyperactivation within smooth muscle cells actively promotes this lipid-laden transformation in the injured arterial wall, linking inflammasome signaling directly to one of the hallmarks of atherosclerosis.

Beneath these observations, the researchers uncovered a possible mechanistic explanation involving cellular housekeeping. The mutant arteries showed reduced expression of transcription factor EB, or TFEB, the master regulator of lysosomal biogenesis and autophagy, along with altered expression of lysosome- and autophagy-related markers. TFEB orchestrates the cell’s waste-disposal and recycling systems, and previous work by some of the same investigators showed that activating TFEB ameliorates smooth muscle dedifferentiation and neointima formation in mice fed a high-fat diet. The new findings suggest that NLRP3 hyperactivation may disrupt these stress-adaptive pathways, leaving smooth muscle cells less able to digest damaged proteins, clear lipids, and maintain their contractile identity during vascular remodeling. The association between inflammasome overactivity and impaired lysosomal-autophagic function offers an attractive framework for understanding how inflammation and metabolic dysfunction reinforce each other in the diseased artery.

The clinical implications are considerable. Cardiovascular disease remains the leading cause of death worldwide, and while statins and the anti-inflammatory antibody canakinumab have demonstrated that taming inflammation reduces cardiovascular events, broadly suppressing the immune system carries risks. The new study suggests that a more precise strategy, targeting NLRP3-associated signaling specifically within vascular smooth muscle cells, could limit restenosis after stenting or bypass grafting and slow plaque progression without wholesale immunosuppression. Several NLRP3 inhibitors are already in development for other inflammatory conditions, and the mouse model created by the Houston and Richmond team provides a platform for testing whether such compounds can keep injured arteries open. As with all murine studies, translation to human patients will require careful validation, and the authors note that their data establish associations alongside causal effects that warrant further mechanistic dissection. Still, by pinpointing a single molecular sensor in a single cell type as a linchpin of arterial thickening, the work transforms our understanding of what happens inside a vessel wall after injury, and it offers a concrete molecular bullseye for the next generation of cardiovascular anti-inflammatory therapies.

Subject of Research: The role of vascular smooth muscle NLRP3 inflammasome hyperactivation in arterial intimal hyperplasia and restenosis

Article Title: Vascular smooth muscle-specific NLRP3 hyperactivation exacerbates arterial intimal hyperplasia in mice

Article References: Wang, Y.-T., Moura, A. K., Zuo, R., Gao, W., McConnell, B. K., Li, G., Li, P.-L., Li, X., & Zhang, Y. (2026). Vascular smooth muscle-specific NLRP3 hyperactivation exacerbates arterial intimal hyperplasia in mice. Journal of Molecular Medicine, 104(1), Article 116. https://doi.org/10.1007/s00109-026-02724-3

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02724-3

Keywords: NLRP3, inflammasome, vascular smooth muscle cells, intimal hyperplasia, restenosis, caspase-1, Gasdermin D, pyroptosis, TFEB, lysosome-autophagy, foam cells, atherosclerosis

Metabolic cardiomyopathy is one of the most consequential cardiovascular complications of diabetes and obesity, quietly raising the risk of heart failure and malignant arrhythmias even before overt symptoms appear. Its core pathology involves a tangle of imbalanced myocardial energy metabolism, lipotoxic injury, and chronic low-grade inflammation that progressively remodels the heart muscle. While epidemiological studies have repeatedly associated diets rich in polyphenols with reduced cardiometabolic risk, the precise cellular mechanisms by which individual plant compounds defend heart cells under metabolic stress have remained murky. The new research set out to close that gap by asking how Sal B behaves when heart cells are bathed in dangerously high levels of glucose.

The team, based at institutions affiliated with Xiamen University and Xiamen ChangGung Hospital in China, worked with AC16 human cardiomyocytes, a widely used laboratory model of heart muscle cells. To mimic the metabolic environment of diabetes, the researchers exposed the cells to glucose concentrations ranging from a physiological 5.5 millimoles per liter up to a pathological 30 millimoles per liter. Cell death rose in a concentration-dependent manner, with the most severe damage at the highest glucose level, confirmed by light microscopy, viability assays, and TUNEL staining that flags fragmented DNA in dying cells.

Before testing protection, the researchers first established a safe working dose. They screened Sal B at concentrations from 10 to 320 micromoles per liter and settled on 40 micromoles per liter, the level that kept cell viability above 90 percent in the absence of stress. When cells were pretreated with Sal B for 24 hours before the high-glucose challenge, the results were striking. Viability recovered significantly, and the flood of proinflammatory cytokines that high glucose normally triggers, including interleukin-1 beta, interleukin-18, and tumor necrosis factor alpha, was substantially blunted in the culture supernatants.

The protective signature extended to oxidative stress, a parallel driver of metabolic heart injury. High glucose depleted superoxide dismutase, a key endogenous antioxidant enzyme, while elevating malondialdehyde, a marker of lipid peroxidation, and lactate dehydrogenase, a proxy for membrane damage. Sal B pretreatment reversed all three indicators and, as measured by flow cytometry with a fluorescent probe, reduced the intracellular accumulation of reactive oxygen species. TUNEL staining confirmed that fewer cells died when the polyphenol was on board, painting a picture of a compound that simultaneously damps oxidative and inflammatory damage.

The mechanistic heart of the study lies in pyroptosis, a form of regulated cell death executed by the gasdermin family of proteins. Under metabolic stress, the NLRP3 inflammasome assembles in cardiomyocytes, activating caspase-1, which in turn cleaves gasdermin D into its pore-forming N-terminal fragment. Those pores rupture the cell membrane and spill inflammatory contents into the surrounding tissue, amplifying injury. In the high-glucose model, the researchers observed the full pyroptotic cascade: elevated mRNA and protein levels of NLRP3, the adaptor protein ASC, cleaved caspase-1, and gasdermin D, together with the release of its active N-terminal fragment. Sal B pretreatment partially reversed every one of these molecular changes.

To identify the upstream switch controlling this cascade, the team turned to bioinformatics. Mining two public transcriptomic datasets from the Gene Expression Omnibus, one from muscle tissue of patients with diabetes and one from white adipose tissue and aortae of obese and atherosclerotic mice, they applied differential expression analysis, weighted gene co-expression network analysis, and intersection with a UniProt gene set for metabolic cardiomyopathy. A single candidate emerged from the overlap: MMP12, an elastin- and fibronectin-cleaving enzyme best known from atherosclerosis research but increasingly implicated in cardiac remodeling and fibrosis. Its expression correlated with inflammatory response and extracellular matrix remodeling signatures, and it discriminated disease status in the discovery cohort, though the authors caution that the small sample size makes the diagnostic performance provisional at best.

Molecular docking simulations then provided a structural rationale for how Sal B might engage MMP12. The polyphenol docked stably into the enzyme’s active cavity with a predicted binding free energy of minus 9.2 kilocalories per mole, well beyond the conventional threshold for favorable binding. Hydrogen bonds with residues Lys233 and Thr239 anchored the molecule, hydrophobic contacts with Phe114 and Leu117 stabilized the pose, and pi-pi stacking with Tyr242 in the S1′ specificity pocket added further grip, all in the vicinity of the catalytic zinc ion that drives the enzyme’s proteolytic activity.

The decisive evidence came from rescue experiments. The researchers engineered a plasmid that forced AC16 cells to overproduce MMP12, verified by Sanger sequencing and confirmed at both the mRNA and protein levels. When MMP12 was overexpressed, Sal B’s protection visibly weakened: TUNEL-positive cell death increased, the suppression of interleukin-1 beta, interleukin-18, and tumor necrosis factor alpha was partially undone, and the protein levels of NLRP3, ASC, cleaved caspase-1, and gasdermin D’s active fragment rebounded. In other words, flooding the cells with MMP12 partially bypassed the polyphenol’s brake on pyroptosis, placing MMP12 functionally upstream of the NLRP3 inflammasome in Sal B’s mechanism of action.

The authors are careful to frame the translational caveats. The 40 micromolar concentration used in the dish far exceeds what ordinary dietary intake achieves in human blood, given the low oral bioavailability of polyphenols, so the findings support mechanistic exploration rather than a dietary prescription. Nano-delivery systems such as liposomes and polymeric nanoparticles, along with the cumulative activity of Sal B’s in vivo metabolites, are proposed as routes to bridge that gap. The Sal B-MMP12 interaction itself rests on docking predictions and functional necessity rather than direct biophysical proof, and the high-glucose model may carry nonspecific osmotic effects that future mannitol control experiments should exclude. Non-canonical pyroptosis pathways and alternative inflammasomes such as AIM2 also remain untested. Even so, the study delivers a compelling preliminary map of how an edible plant polyphenol intercepts the MMP12-NLRP3-pyroptosis axis, offering a mechanistic foundation for functional food ingredients aimed at cardiometabolic health.

Subject of Research: Cytoprotective mechanisms of the plant polyphenol salvianolic acid B against high-glucose-induced cardiomyocyte pyroptosis via the MMP12–NLRP3 signaling axis

Article Title: Plant‐Derived Polyphenol Salvianolic Acid B Attenuates Cardiomyocyte Pyroptosis by Modulating the MMP12–NLRP3 Signaling Axis

Article References: Xie, Z., Yang, Z.-K., Zheng, L., Wu, P., Chen, S., Ye, X., & Gao, Y. (2026). Plant‐Derived Polyphenol Salvianolic Acid B Attenuates Cardiomyocyte Pyroptosis by Modulating the MMP12 – NLRP3 Signaling Axis. Food Science & Nutrition, 14(10), Article e72300. https://doi.org/10.1002/fsn3.72300

Image Credits: AI Generated

DOI: 10.1002/fsn3.72300

Keywords: salvianolic acid B, metabolic cardiomyopathy, pyroptosis, NLRP3 inflammasome, MMP12, cardiomyocytes, polyphenols, oxidative stress, diabetes, gasdermin D, molecular docking, functional foods

Pyroptosis is no ordinary cell death. Unlike apoptosis, the quiet, tidy form of programmed cell death in which cells shrink and are neatly consumed by their neighbors, pyroptosis is loud, lytic, and inflammatory. The pathway is evolutionarily conserved among eukaryotic cells and is executed by caspases—a family of proteolytic enzymes—ultimately leading to the formation of pores in the cell’s plasma membrane by members of the gasdermin protein family. When gasdermin D, the best-characterized executioner, is cleaved by inflammatory caspases such as caspase-1 or caspase-11 in mice (and caspase-4 and caspase-5 in humans), its pore-forming fragments insert into the membrane. Water rushes in, the cell swells, and it eventually ruptures, spilling its contents into the surrounding tissue.

That spill is precisely what makes pyroptosis so consequential. Among the released contents are interleukin-1β and interleukin-18, potent pro-inflammatory cytokines that are processed and activated by caspase-1 within large multiprotein signaling platforms called inflammasomes. The prototypical NLRP3 inflammasome assembles from the sensor protein NLRP3, the adaptor ASC, and caspase-1, forming supramolecular complexes sometimes described as pyroptosomes. Other inflammasomes, including NLRC4, AIM2, and NLRP1, respond to different danger signals ranging from bacterial flagellin to cytosolic DNA. In the right context—say, an intracellular bacterial infection—this explosive death is a defensive triumph, denying pathogens their replicative niche and rallying immune cells to the site. But when pyroptosis fires in the wrong place or cannot be switched off, it becomes a source of collateral tissue damage, a theme now documented in conditions from sepsis to atherosclerosis to neurodegeneration.

The ovary, the review argues, is exquisitely vulnerable to this kind of inflammatory friendly fire. Female infertility and ovarian dysfunction are closely associated with inflammation, and the ovarian follicle’s functional unit depends on granulosa cells—somatic cells that nurture the developing oocyte, mediate hormone production, and orchestrate ovulation. When granulosa cells undergo pyroptosis, the follicle loses its support system. Evidence cited in the review points to activation of the NLRP3/caspase-1/gasdermin D axis in granulosa cells across several major ovarian pathologies, including polycystic ovary syndrome (PCOS), premature ovarian insufficiency (POI), and diminished ovarian reserve. In PCOS, upregulation of TXNIP, a protein that links oxidative stress to inflammasome activation, contributes to granulosa cell dysfunction through NLRP3 activation. Hyperandrogenism, a hallmark of PCOS, has itself been shown to drive ovarian inflammation and pyroptosis, with the mechanistic target of rapamycin-linked YAP signaling implicated in follicular dysfunction.

The molecular wiring connecting metabolic stress to pyroptotic death in the ovary is becoming increasingly detailed. Oxidative stress is a central node: reactive oxygen species can trigger NLRP3 inflammasome assembly, and oxidized mitochondrial DNA released from damaged mitochondria serves as a potent inflammasome activator. The TXNIP protein acts as a molecular switch, dissociating from thioredoxin under oxidative stress and binding NLRP3 to ignite the inflammasome. Endoplasmic reticulum stress adds another layer, with the IRE1α pathway inducing TXNIP expression under irremediable stress conditions. In overweight women, local glucose elevation in the ovarian environment has been shown to activate NLRP3-dependent pyroptosis in granulosa cells, tying metabolic disease directly to reproductive cell death. Even the gut microbiome appears to play a role: microbiota dysbiosis-derived macrophage pyroptosis has been linked to PCOS through disturbance of steroidogenesis and apoptosis of granulosa cells.

The clinical stakes are considerable. Premature ovarian insufficiency—the loss of ovarian function before age forty—affects roughly one percent of women and carries profound consequences for fertility, bone health, and cardiovascular risk. Diminished ovarian reserve, a subtler depletion of the follicular pool, is among the most frustrating diagnoses in reproductive medicine, and inflammatory and oxidative stress markers measured in follicular fluid correlate with its severity. Inflamm-aging, the chronic low-grade inflammatory state that accompanies advancing age, has been proposed as a mechanism accelerating POI. The review also notes that inflammasome components are elevated in granulosa cells and follicular fluid of women with endometriosis undergoing in vitro fertilization, and that a proinflammatory M1 macrophage phenotype with NLRC4 inflammasome activation is associated with impaired oocyte fertilization. More recently, IFN-γ-induced AIM2-dependent PANoptosis—a hybrid inflammatory death program—has been implicated in ovulatory dysfunction in PCOS, underscoring that pyroptosis is one node in a broader, interconnected network of inflammatory cell death pathways that also includes necroptosis and ferroptosis.

What elevates the review beyond mechanism is its survey of therapeutics. Because each step of the pyroptotic cascade is pharmacologically addressable, a growing list of compounds has shown promise in preclinical models of ovarian disease. Nicotinamide mononucleotide (NMN), a precursor of the NAD+ cofactor, improved ovarian reserve in models of POI by inhibiting NLRP3-mediated pyroptosis of ovarian granulosa cells, consistent with a broader literature linking NAD+ metabolism to inflammasome regulation through acetylation switches. The natural compound plumbagin rescued granulosa cell pyroptosis in PCOS by reducing WTAP-mediated N6-methylation, pointing to an epitranscriptomic layer of control. Quercetin, a widely available flavonoid, alleviated cyclophosphamide-induced premature ovarian insufficiency in mice by reducing mitochondrial oxidative stress and pyroptosis in granulosa cells. Cyproterone acetate, an antiandrogen, mediated the IRE1α signaling pathway to alleviate hyperandrogen-induced granulosa cell pyroptosis. The metabolite α-ketoglutarate improved ovarian reserve function in primary ovarian insufficiency by inhibiting NLRP3-mediated pyroptosis, while itaconic acid—classically an anti-inflammatory immunometabolite—prevented ovarian damage in diminished ovarian reserve models through NRF2-mediated pathways. Resveratrol alleviated inflammation in PCOS by inhibiting AIM2 expression, and metformin inhibited granulosa cell pyroptosis through a microRNA/NOX2/ROS pathway, suggesting that established metabolic drugs may carry unexpected reproductive benefits.

Perhaps the most futuristic entry in the therapeutic lineup comes from regenerative medicine. Exosomes—nanoscale extracellular vesicles that shuttle proteins, lipids, and nucleic acids between cells—derived from mesenchymal stem cells have been shown to attenuate NLRP3-related pyroptosis in autoimmune premature ovarian insufficiency via the NF-κB pathway. Stem cell approaches more broadly, including adipose-derived stem cells that repair chemotherapy-induced ovarian failure by inhibiting granulosa cell apoptosis and senescence, are being reinterpreted through the pyroptosis lens. Even moxibustion, the traditional practice of burning mugwort near acupuncture points, has been reported to protect against cyclophosphamide-induced premature ovarian failure in rats by inhibiting the NLRP3/caspase-1/GSDMD-dependent pyroptotic axis—an intriguing convergence of ancient practice and molecular mechanism, though the authors of the underlying work acknowledge that clinical translation remains distant and that rigorous trials are needed.

The review is candid about the gaps that remain. Most of the therapeutic evidence comes from rodent models and cultured granulosa cell lines, which imperfectly recapitulate human follicular biology; human granulosa cell lines differ meaningfully from primary cells in their endocrine profiles. Biomarkers of pyroptosis that could be measured in follicular fluid or blood to stratify patients are still lacking, and the crosstalk between pyroptosis and the other regulated death pathways—apoptosis, necroptosis, ferroptosis, and PANoptosis—in the ovary is only beginning to be mapped. Distinguishing protective from pathological pyroptosis will be essential, since complete blockade of an innate immune defense pathway carries its own risks, a lesson learned from inflammasome drug development in other inflammatory diseases. The authors call for systematic investigation of gasdermin-independent pyroptotic routes, better tools for monitoring pyroptosis dynamics in living tissue, and ultimately clinical trials that test whether pyroptosis-targeted interventions can genuinely improve fertility outcomes.

Still, the conceptual shift is hard to overstate. For decades, infertility treatment has focused on manipulating hormones and retrieving oocytes, with inflammation treated as background noise. If pyroptosis proves to be a central, druggable driver of follicular demise, then a prescription pad that once held only gonadotropins and metformin might one day include NLRP3 inhibitors, gasdermin blockers, NAD+ boosters, and engineered exosomes designed to quiet the inflammatory storm inside the ovary. The review by Ajoolabady and colleagues does not claim that a cure is at hand, but it makes a compelling case that the molecular arsonist behind ovarian failure has finally been identified—and that the tools to extinguish it are already within reach.

Subject of Research: The role of pyroptosis, an inflammatory form of programmed cell death, in ovarian dysfunction and female infertility

Article Title: Pyroptosis in Patients with Ovarian Dysfunction and Infertility: Molecular Mechanisms and Therapeutics

Article References: Ajoolabady, A., Kim, B., Tuomilehto, J., Pratico, D., Ren, J., & Harrath, A. H. (2026). Pyroptosis in Patients with Ovarian Dysfunction and Infertility: Molecular Mechanisms and Therapeutics. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02208-2

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02208-2

Keywords: pyroptosis, ovarian dysfunction, infertility, NLRP3 inflammasome, gasdermin D, granulosa cells, polycystic ovary syndrome, premature ovarian insufficiency, inflammation, caspase-1, nicotinamide mononucleotide, exosomes

The study, led by Qingtao Ni, Xiuyuan Yang, and Jingjing Bao, with corresponding author Chi Pan of The Affiliated Taizhou People’s Hospital of Nanjing Medical University, focuses on pyroptosis, a form of programmed cell death that has captivated cancer biologists in recent years. Unlike apoptosis, the quiet and orderly demise that most cell death research has traditionally centered on, pyroptosis is loud and destructive. Cells undergoing pyroptosis swell, rupture, and spill their contents into the surrounding tissue, triggering a potent inflammatory response. This explosive exit is orchestrated by members of the gasdermin family of proteins, which form pores in the cell membrane, and by inflammatory caspases such as caspase-1, which cleave those gasdermins into their active forms. The released cellular contents, including signaling molecules such as interleukin-1 beta and interleukin-18, can alert the immune system to danger. For tumor cells, this is often a catastrophic event, which is precisely why oncologists are interested in learning how to switch it on deliberately.

Yet the regulatory mechanisms governing pyroptosis in triple-negative breast cancer have remained poorly charted. To map them, the researchers began with an integrated bioinformatics analysis of publicly available gene expression datasets from the Gene Expression Omnibus, hunting for genes that are differentially expressed in breast cancer tissue compared with healthy tissue. From this screen, one gene stood out as a hub of malignant activity: MELK, short for maternal embryonic leucine zipper kinase. The team confirmed in clinical triple-negative breast cancer specimens that MELK is significantly upregulated in these tumors, and that elevated levels are associated with more advanced disease and poorer prognosis. Functionally, when the researchers manipulated MELK levels in triple-negative breast cancer cell lines, they found that the kinase actively promoted the hallmarks of cancer aggression: proliferation, migration, and invasion.

On the other side of the balance sat a microRNA. MicroRNAs are short, non-coding RNA molecules, roughly 22 nucleotides long, that do not encode proteins but instead regulate gene expression after transcription. They bind to complementary sequences in messenger RNA transcripts, marking them for degradation or blocking their translation into protein. A single microRNA can thereby tune the output of dozens of genes simultaneously. The microRNA in question here, miR-205-3p, was frequently found at reduced levels in triple-negative breast cancer samples, a pattern consistent with a tumor-suppressive role. When the researchers restored or elevated miR-205-3p in triple-negative breast cancer cell lines, the effect was striking: the cells underwent caspase-1-dependent pyroptosis, a conclusion supported by the appearance of cleaved fragments of both gasdermin D and gasdermin E, the executioner proteins of the pyroptotic pathway, as well as the release of interleukin-1 beta and interleukin-18 measured by Western blotting and enzyme-linked immunosorbent assay.

A natural question followed: was miR-205-3p simply silencing MELK directly? The answer, perhaps surprisingly, was no. Although MELK overexpression partially reversed the suppression of malignant behavior caused by miR-205-3p, the team’s experiments, including a dual-luciferase reporter assay, a standard technique for verifying direct binding between a microRNA and its target transcript, showed that miR-205-3p does not directly target MELK. Instead, the true direct target turned out to be a different molecule entirely: HSP90AB1, the heat shock protein 90 alpha family class B member 1, a molecular chaperone best known for stabilizing a wide array of client proteins inside the cell. The reporter assays confirmed that miR-205-3p binds directly to HSP90AB1 transcripts and represses their expression.

This discovery reframed the entire regulatory architecture. HSP90AB1, it emerged, sits at the center of a tug-of-war between the tumor-suppressive microRNA and the oncogenic kinase. The researchers found that MELK positively regulates HSP90AB1, enhancing its expression, and that this enhancement serves to inhibit the pyroptotic pathway. In other words, MELK protects triple-negative breast cancer cells from inflammatory self-destruction by keeping the chaperone abundant, while miR-205-3p promotes pyroptosis by stripping that protection away. When miR-205-3p represses HSP90AB1, the downstream gasdermin D and gasdermin E cleavage cascade is unleashed, and the cell dies by pyroptosis. When MELK is abundant and drives HSP90AB1 upward, the miR-205-3p/HSP90AB1/GSDMD axis is suppressed, and the cell survives to proliferate, migrate, and invade.

The interplay between these two regulators through their shared target ultimately determines cellular fate, the authors conclude. This kind of indirect antagonism, in which a microRNA and a kinase converge on a common downstream effector rather than on each other, adds a layer of nuance to how researchers think about microRNA-mediated tumor suppression. It also helps explain why MELK has repeatedly surfaced in cancer studies as a driver of malignancy: beyond its established roles in cell cycle control and signaling, it appears to function as a critical upstream brake on pyroptosis, keeping tumor cells from triggering the inflammatory form of death that would otherwise expose them to immune attack.

The therapeutic implications are considerable. Triple-negative breast cancer has long been an attractive candidate for immunotherapy and other novel approaches precisely because its inflammatory microenvironment, when it exists, correlates with better responses. If pyroptosis can be pharmacologically induced in these tumors, the resulting release of damage-associated molecular patterns and inflammatory interleukins could convert a cold tumor into a hot one, recruiting immune cells to the site of disease. The newly described miR-205-3p/HSP90AB1/GSDMD axis offers several potential intervention points: restoring miR-205-3p activity, inhibiting MELK, or directly targeting HSP90AB1 function. MELK inhibitors have already attracted attention in drug development pipelines, and the present study provides a fresh mechanistic rationale for exploring them in triple-negative breast cancer, not merely as anti-proliferative agents but as sensitizers of immunogenic cell death.

As with all laboratory studies, the path from cell culture to clinic is long. The experiments relied on established triple-negative breast cancer cell lines and clinical specimens, and the authors note that the work was approved by the Ethical Committee of Jiangsu Taizhou People’s Hospital with written informed consent from participants. Delivering microRNA mimics to tumors remains a formidable delivery challenge, and the precise consequences of triggering pyroptosis in a living tumor, where inflammatory signals can sometimes fuel growth as easily as they can ignite immune clearance, will require careful evaluation in animal models and, eventually, clinical trials. Still, the study adds an important piece to the puzzle of why triple-negative breast cancer cells resist death, and it identifies a concrete molecular switch—HSP90AB1, poised between a protective kinase and a lethal microRNA—that future therapies might one day flip. For patients facing the hardest-to-treat form of breast cancer, that switch represents a genuinely new lead.

Subject of Research: The regulatory mechanism by which miR-205-3p induces pyroptosis in triple-negative breast cancer through HSP90AB1 and antagonism of MELK.

Article Title: miR-205-3p induces pyroptosis in triple-negative breast cancer by targeting HSP90AB1 and antagonizing MELK

Article References: Ni, Q., Yang, X., Bao, J., Yi, T., & Pan, C. (2026). miR-205-3p induces pyroptosis in triple-negative breast cancer by targeting HSP90AB1 and antagonizing MELK. BMC Cancer. https://doi.org/10.1186/s12885-026-17028-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17028-5

Keywords: triple-negative breast cancer, pyroptosis, miR-205-3p, HSP90AB1, MELK, gasdermin D, gasdermin E, caspase-1, microRNA, tumor suppression, cell death, BMC Cancer

Microglia are the sentinels of the central nervous system. In the healthy brain they patrol their territory with ramified processes, sampling the microenvironment for signs of danger. When ischemia strikes, they rapidly shift into an activated state, and for years researchers described this shift using a binary model: pro-inflammatory M1-like microglia that amplify tissue damage, and anti-inflammatory M2-like microglia that promote repair. The new review argues that this tidy dichotomy has outlived its usefulness. Single-cell sequencing studies have revealed a far richer spectrum of microglial subtypes, each with distinct transcriptional profiles, metabolic preferences, and functional consequences. Polarization, in this view, is not a switch but a continuum—a dynamic landscape of states that cells occupy, abandon, and re-enter as the post-stroke environment evolves.

At the heart of this transformation lies a profound metabolic reprogramming. Resting microglia rely primarily on oxidative phosphorylation, the efficient mitochondrial process that converts nutrients into ATP. After ischemia, however, oxygen and glucose scarcity forces a shift toward aerobic glycolysis, the same fermentative strategy that Warburg observed in cancer cells. This metabolic pivot is orchestrated in large part by hypoxia-inducible factor 1-alpha, or HIF-1α, which stabilizes under low-oxygen conditions and drives expression of glycolytic enzymes such as hexokinase 2. The result is a cell that burns glucose wastefully but rapidly, generating the biosynthetic intermediates and NADPH it needs to fuel an immune response—while simultaneously producing lactate and succinate as metabolic byproducts with signaling roles of their own.

The review pays particular attention to mitochondria, which are not merely passive casualties of ischemia but active participants in the inflammatory cascade. Under normal conditions, a network of mitochondrial quality control mechanisms—collectively termed MQC—keeps these organelles healthy. Mitochondrial dynamics, the constant fission and fusion of the network, allow damaged segments to be segregated. Mitophagy, guided by the PINK1-Parkin pathway, then removes severely compromised mitochondria before they can do harm. Ischemia disrupts this surveillance system. The mitochondrial permeability transition pore opens, membrane potential collapses, and the quality control machinery becomes overwhelmed. The consequence is the release of a battery of mitochondrial damage-associated molecular patterns: reactive oxygen species generated at the electron transport chain, fragments of oxidized mitochondrial DNA, and cardiolipin, a phospholipid normally confined to the inner mitochondrial membrane that becomes a potent danger signal when exposed to the cytosol.

These mitochondrial alarm signals converge on one of the most consequential immune complexes known: the NLRP3 inflammasome. NLRP3, a cytosolic pattern-recognition receptor, assembles with the adaptor protein ASC and procaspase-1 into a multi-protein platform that activates caspase-1. The review highlights how several metabolic and mitochondrial cues converge to trigger this assembly. Succinate, which accumulates during ischemia, can drive reverse electron transport through mitochondrial complex I, supercharging the production of mitochondrial reactive oxygen species. Oxidized mitochondrial DNA binds directly to NLRP3. Extracellular lactate and cytosolic cardiolipin provide additional priming and activation signals. Once assembled, the inflammasome executes its inflammatory program: caspase-1 cleaves pro-interleukin-1β and pro-interleukin-18 into their mature, secreted forms, and cleaves gasdermin D to release its N-terminal fragment, GSDMD-NT.

What happens next is where the review makes its most striking conceptual contribution. GSDMD-NT is not simply a bystander in inflammation—it migrates to the mitochondria and perforates both the inner and outer mitochondrial membranes, forming pores that further destabilize these organelles. This establishes a self-amplifying positive feedback loop: mitochondrial damage releases the signals that activate the NLRP3 inflammasome, and inflammasome activation inflicts further mitochondrial damage. In the ischemic brain, where microglia are already metabolically stressed, this loop can lock the cell into a hyperinflammatory state that persists long after the initial insult. The authors also note that activated mitochondrial DNA can engage the STING pathway, adding an interferon-mediated dimension to the inflammatory response and further entrenching the pro-inflammatory phenotype.

Crucially, the review insists that this axis cannot be understood without considering time. The authors stratify the MQC–metabolism–inflammation network into three temporal phases. In the hyperacute phase, within minutes to hours of vessel occlusion, energy failure and mitochondrial permeability transition dominate, and the earliest danger signals are released. In the subacute phase, spanning hours to days, microglial polarization reaches its peak, glycolytic reprogramming is fully established, and NLRP3-driven cytokine release shapes the evolving lesion. In the chronic phase, weeks to months later, a lingering population of chronically activated microglia sustains low-grade inflammation that interferes with tissue remodeling and repair. Each phase, the authors argue, presents distinct therapeutic windows and distinct molecular targets, and interventions that ignore this temporal structure are unlikely to succeed.

The review is also refreshingly candid about the translational bottlenecks that have stalled progress from bench to bedside. Numerous NLRP3 inhibitors and mitochondrial protective agents have shown promise in rodent models of stroke, yet clinical trials have repeatedly disappointed. One reason, the authors emphasize, lies in fundamental differences between mice and humans. The NLRP3 inflammasome and its regulatory feedback mechanisms differ in important ways between the two species, meaning that regulatory circuits mapped in mouse models must be interpreted with caution before being extrapolated to patients. The authors call for humanized models and bidirectional clinical validation to close this gap, alongside single-cell multi-omics approaches to map the full diversity of microglial subpopulations in the human ischemic brain, and metabolic flux analysis to quantify the actual thresholds at which metabolites such as succinate and lactate become pathogenic.

Two testable hypotheses emerge from the framework. The first proposes that the strength and duration of the mitochondrial damage–inflammasome feedback loop determines whether microglia resolve toward a reparative phenotype or remain trapped in a chronic inflammatory state—suggesting that early stabilization of mitochondrial quality control could steer the entire trajectory of post-stroke inflammation. The second proposes that specific metabolite thresholds, rather than bulk shifts in metabolic pathway activity, are the critical determinants of NLRP3 activation, implying that precise quantification of metabolite flux in individual microglial subtypes will be essential for rational drug design. Both hypotheses lend themselves to direct experimental interrogation with the tools now available, from metabolomics to live imaging of mitochondrial dynamics.

For a field that has long treated metabolism, mitochondria, and inflammation as separate chapters of the stroke story, this integrated framework offers something genuinely new: a systems-level map of how the pieces fit together in space and time. If the hypotheses hold up, the implications extend beyond ischemic stroke to any neurological condition in which microglial metabolism and inflammasome activation run amok, from traumatic brain injury to neurodegenerative disease. The therapeutic challenge remains formidable—timing interventions to the right phase, achieving selectivity for pathogenic microglial states, and bridging the species divide—but the review provides a clear conceptual scaffold on which the next generation of experiments, and perhaps eventually therapies, can be built.

Subject of Research: Microglial metabolic reprogramming, mitochondrial dysfunction, and NLRP3 inflammasome activation in cerebral ischemia

Article Title: Metabolic reprogramming and polarization of microglia in cerebral ischemia: the roles of mitochondria and inflammasomes

Article References: Ding, Y., Li, N., Li, Q., Zhang, H., He, L., Gao, F., & Li, P. (2026). Metabolic reprogramming and polarization of microglia in cerebral ischemia: the roles of mitochondria and inflammasomes. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08947-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08947-9

Keywords: ischemic stroke, microglia, mitochondrial quality control, metabolic reprogramming, NLRP3 inflammasome, neuroinflammation, mitochondrial dysfunction, aerobic glycolysis, gasdermin D, single-cell sequencing, HIF-1alpha, neuroimmunology

Inflammasomes are cytosolic signaling complexes assembled by pattern recognition receptors in response to a wide array of danger-associated and pathogen-associated molecular patterns. Among the best characterized is the NLRP3 inflammasome, which can be activated by an extraordinary diversity of stimuli, ranging from extracellular ATP and crystalline substances such as monosodium urate to perturbations in cellular homeostasis including mitochondrial dysfunction and ionic flux. Structural studies, notably cryo-electron microscopy analyses, have revealed that NLRP3 oligomerizes into a large ring-like platform that recruits the adaptor protein ASC through pyrin domain interactions. ASC in turn nucleates the polymerization of procaspase-1 filaments through its caspase recruitment domain, creating a branched, star-shaped assembly that has become iconic in the field of innate immunity.

The review emphasizes how this hierarchical assembly process, in which a receptor seeds adaptor polymerization which then seeds effector activation, is a recurring architectural principle across inflammasome families. DNA-sensing receptors such as AIM2 and the Pyrin family of receptors, as well as the more recently described sensors like NLRP1 and CARD8, all converge on the same downstream machinery despite recognizing fundamentally different ligands. This convergence explains how a limited set of adaptor and effector molecules can translate an enormous diversity of upstream danger signals into a uniform cellular response: the activation of inflammatory caspases, cleavage of the cytokine precursors pro-interleukin-1 beta and pro-interleukin-18, and induction of a lytic form of cell death known as pyroptosis.

Pyroptosis itself has been structurally dissected at the level of its executioner, gasdermin D. Activated inflammatory caspases cleave gasdermin D to release an N-terminal fragment that oligomerizes into membrane pores, causing osmotic lysis and the release of intracellular contents, including mature interleukin-1 beta. Recent structures of gasdermin pores have clarified how the positively charged face of the oligomer interacts with membrane lipids and how pore formation is regulated. This level of mechanistic detail has direct pharmacological implications, because small molecules that block gasdermin pore formation or inflammasome assembly could dampen pathological inflammation in conditions as varied as gout, atherosclerosis, type 2 diabetes, inflammatory bowel disease, and neurodegenerative disease, all of which have been linked to excessive inflammasome activity.

Beyond canonical inflammasomes, the review devotes substantial attention to PANoptosis, a recently articulated form of inflammatory programmed cell death that integrates features of pyroptosis, apoptosis, and necroptosis within a single, coordinated complex termed the PANoptosome. Unlike a classical inflammasome, a PANoptosome contains components from multiple cell death pathways simultaneously, including Z-DNA-binding protein 1, or ZBP1, which senses Z-form nucleic acids generated during viral infection, together with receptor-interacting protein kinases and other death-domain proteins. Structural and biochemical studies suggest that these complexes assemble through a web of homotypic and heterotypic domain interactions, creating a platform capable of activating multiple death effector machineries in parallel and amplifying inflammatory signaling to a degree that neither pathway could achieve alone.

ZBP1 has emerged as a particularly instructive example of how structural insights inform PANoptosome biology. Its two Z-nucleic acid binding domains recognize the unusual left-handed conformation of Z-DNA and Z-RNA, which accumulates in cells infected with viruses such as influenza A. Upon ligand binding, ZBP1 engages RIPK3 through RHIM domain interactions, and in certain contexts also recruits NLRP3 and ASC, thereby coupling viral sensing directly to necroptosis, pyroptosis, and cytokine release. Mutations that disrupt these interactions protect mice from lethal influenza-associated inflammation, underscoring the in vivo importance of this pathway and highlighting RHIM-mediated interactions as a potential drug target in severe viral pneumonia and other contexts of pathogenic inflammation.

One of the central themes of the review is that autoinhibition is a universal feature of innate immune sensors, reflecting the danger of accidental self-destruction if these potent inflammatory pathways are triggered spuriously. NLRP3, for example, is held in an inactive conformation by its LRR domain folding back onto the nucleotide-binding domain, a constraint released through a multi-step activation process involving NEK7 binding, deubiquitination, and translocation to the Golgi or endosomal membranes. Similar autoinhibitory mechanisms govern NLRP1, which releases its inhibitory function upon proteasomal degradation of an N-terminal regulatory segment, and pyrin, which is restrained by phosphorylation-dependent sequestration through binding to 14-3-3 proteins. Structural biology has provided atomic-level explanations for how disease-associated mutations, including those causing cryopyrin-associated periodic syndromes and familial Mediterranean fever, destabilize these autoinhibited states and drive constitutive inflammasome activation.

The therapeutic implications of this structural knowledge are considerable and span several classes of intervention. Direct inhibitors of NLRP3, such as MCC950 and its derivatives, have demonstrated efficacy in preclinical models of numerous inflammatory diseases and are progressing through clinical evaluation. Second-generation approaches include compounds that block ASC speck formation, inhibitors of inflammatory caspases, gasdermin D antagonists designed to prevent pore formation, and agents targeting upstream cytokine signaling through blockade of interleukin-1 family receptors. For PANoptosome-driven diseases, particularly severe viral infections and certain hereditary autoinflammatory syndromes, strategies that interrupt specific protein-protein interfaces, such as the RHIM-dependent interaction between ZBP1 and RIPK3, represent an emerging frontier. The review argues that structural data, by revealing precisely where and how these complexes assemble, will be indispensable for the rational design of such inhibitors.

Challenges nonetheless remain substantial. Inflammasome components are large, flexible, and often membrane-associated, complicating structural determination of full assemblies in physiologically relevant states. Much of the available structural information derives from isolated domains, truncated constructs, or oligomers assembled in vitro, and bridging the gap between these reductionist structures and the behavior of intact complexes in living cells remains a priority. Moreover, the redundancy and interconnection of inflammatory cell death pathways mean that blocking one arm may simply redirect signaling through another, arguing for combination approaches informed by a systems-level understanding of PANoptosome architecture and regulation.

Taken together, the review frames inflammasomes and PANoptosomes not as isolated curiosities of innate immunity but as a structurally unified family of molecular decision-making machines whose misregulation underlies a broad spectrum of human disease. As cryo-electron microscopy, cryogenic electron tomography, and single-molecule imaging continue to reveal these assemblies at ever higher resolution in increasingly native contexts, the prospect of precisely targeted anti-inflammatory therapeutics, capable of silencing pathological inflammation while preserving beneficial host defense, moves steadily closer to reality.

Subject of Research: Structural and mechanistic analysis of innate immune sensors that assemble inflammasomes and PANoptosomes

Article Title: Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications

Article References: Upadhyay, S., Nagampalli, R., Resende, S., & Kanneganti, T.-D. (2026). Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications. Cell Research. https://doi.org/10.1038/s41422-026-01287-9

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01287-9

Keywords: innate immunity, inflammasome, PANoptosis, PANoptosome, NLRP3, ZBP1, ASC, caspase-1, gasdermin D, pyroptosis, structural biology, anti-inflammatory therapeutics